Citations (96)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Lingyue Zhao, Qian Yang, Yiqun Tang, Qidong You & Xiaoke Guo. (2022) Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 462-471.
Read now
Read now
Alessandro Capucci, Laura Cipolletta, Federico Guerra & Irene Giannini. (2018) Emerging pharmacotherapies for the treatment of atrial fibrillation. Expert Opinion on Emerging Drugs 23:1, pages 25-36.
Read now
Read now
Jules C. Hancox, Andrew F. James, Neil V. Marrion, Henggui Zhang & Dierk Thomas. (2016) Novel ion channel targets in atrial fibrillation. Expert Opinion on Therapeutic Targets 20:8, pages 947-958.
Read now
Read now
Federico Guerra, Maria Vittoria Matassini, Lorena Scappini, Alessia Urbinati & Alessandro Capucci. (2014) Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. Expert Review of Cardiovascular Therapy 12:9, pages 1067-1075.
Read now
Read now
Yukiomi Tsuji & Dobromir Dobrev. (2013) Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Vascular Health and Risk Management 9, pages 165-175.
Read now
Read now
Neil A Castle. (2010) Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy. Expert Opinion on Therapeutic Patents 20:11, pages 1471-1503.
Read now
Read now
Andrew Tinker & Stephen C Harmer. (2010) K+ channels in the heart: new insights and therapeutic implications. Expert Review of Clinical Pharmacology 3:3, pages 305-319.
Read now
Read now
Dariusz Kozlowski, Szymon Budrejko, Gregory YH Lip, Dimitri P Mikhailidis, Jacek Rysz, Grzegorz Raczak & Maciej Banach. (2009) Vernakalant hydrochloride for the treatment of atrial fibrillation. Expert Opinion on Investigational Drugs 18:12, pages 1929-1937.
Read now
Read now
Alexander Burashnikov & Charles Antzelevitch. (2009) Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opinion on Emerging Drugs 14:2, pages 233-249.
Read now
Read now
Juan Tamargo, Ricardo Caballero, Ricardo Gómez & Eva Delpón. (2009) IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opinion on Investigational Drugs 18:4, pages 399-416.
Read now
Read now
Gerald V Naccarelli, Deborah L Wolbrette, Soraya Samii, Javier E Banchs, Erica Penny-Peterson, Robert Stevenson & Mario D Gonzalez. (2008) Vernakalant – a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opinion on Investigational Drugs 17:5, pages 805-810.
Read now
Read now
Qian Yang, Xiaojian Wang, Lupei Du, Minyong Li & Qidong You. (2007) Strategies for atrial fibrillation therapy: focusing on IKur potassium channel. Expert Opinion on Therapeutic Patents 17:12, pages 1443-1456.
Read now
Read now
Articles from other publishers (84)
Assad Shiti, Gil Arbil, Naim Shaheen, Irit Huber, Noga Setter & Lior Gepstein. (2023) Utilizing human induced pluripotent stem cells to study atrial arrhythmias in the short QT syndrome. Journal of Molecular and Cellular Cardiology.
Crossref
Crossref
Andrew Allan, Jeffery Creech, Christian Hausner, Peyton Krajcarski, Bianca Gunawan, Noah Poulin, Paul Kozlowski, Christopher Wayne Clark, Rachel Dow, Prakaimuk Saraithong, Devin B. Mair, Travis Block, Andre Monteiro da Rocha, Deok-Ho Kim & Todd J. Herron. (2023) High-throughput longitudinal electrophysiology screening of mature chamber-specific hiPSC-CMs using optical mapping. iScience 26:7, pages 107142.
Crossref
Crossref
Hindol Mazumdar, Rudranil Bhowmik, Md. Adil Shaharyar, Avishek Mandal, Kumar Anand, Susmita Patra, Reshma Kumari, Sandipan Jana, Pallab Kanti Haldar & Sanmoy Karmakar. 2023. How Synthetic Drugs Work. How Synthetic Drugs Work
289
327
.
Ursula Ravens & Rémi Peyronnet. 2023. Heart Rate and Rhythm. Heart Rate and Rhythm
551
565
.
Shira Burg & Bernard Attali. (2021) Targeting of Potassium Channels in Cardiac Arrhythmias. Trends in Pharmacological Sciences 42:6, pages 491-506.
Crossref
Crossref
Manuel Kraft, Antonius Büscher, Felix Wiedmann, Yannick L’hoste, Walter E. Haefeli, Norbert Frey, Hugo A. Katus & Constanze Schmidt. (2021) Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option. Frontiers in Pharmacology 12.
Crossref
Crossref
Leona A Ritchie, Shuguang Qin, Peter E Penson, Neil C Henney & Gregory YH Lip. (2020) Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. Future Cardiology 16:6, pages 585-595.
Crossref
Crossref
Juan Tamargo. 2020. Antiarrhythmic Drugs. Antiarrhythmic Drugs
265
306
.
Antoine Kossaify. (2019) Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy. Drug Target Insights 13, pages 117739281986111.
Crossref
Crossref
Ingo Staudacher, Claudius Illg, Sam Chai, Isabelle Deschenes, Sebastian Seehausen, Dominik Gramlich, Mara Elena Müller, Teresa Wieder, Ann-Kathrin Rahm, Christina Mayer, Patrick A. Schweizer, Hugo A. Katus & Dierk Thomas. (2018) Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels. Naunyn-Schmiedeberg's Archives of Pharmacology 391:10, pages 1119-1131.
Crossref
Crossref
Márcia Vagos, Ilsbeth G. M. van Herck, Joakim Sundnes, Hermenegild J. Arevalo, Andrew G. Edwards & Jussi T. Koivumäki. (2018) Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future Challenges. Frontiers in Physiology 9.
Crossref
Crossref
Tamer Akel & James Lafferty. (2018) Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis. Annals of Noninvasive Electrocardiology 23:3, pages e12508.
Crossref
Crossref
Alexander Burashnikov. (2017) Late INa Inhibition as an Antiarrhythmic Strategy. Journal of Cardiovascular Pharmacology 70:3, pages 159-167.
Crossref
Crossref
Nipavan Chiamvimonvat, Ye Chen-Izu, Colleen E. Clancy, Isabelle Deschenes, Dobromir Dobrev, Jordi Heijman, Leighton Izu, Zhilin Qu, Crystal M. Ripplinger, Jamie I. Vandenberg, James N. Weiss, Gideon Koren, Tamas Banyasz, Eleonora Grandi, Michael C. Sanguinetti, Donald M. Bers & Jeanne M. Nerbonne. (2017) Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics. The Journal of Physiology 595:7, pages 2229-2252.
Crossref
Crossref
Andreas M?ssigbrodt, Silke John, Jedrzej Kosiuk, Sergio Richter, Gerhard Hindricks & Andreas Bollmann. (2016) Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace 18:1, pages 51-56.
Crossref
Crossref
Maria Vittoria Matassini, Federico Guerra, Lorena Scappini, Alessia Urbinati & Alessandro Capucci. (2015) New anthyarrhythmic drugs for atrial fibrillation. Future Cardiology 11:6, pages 705-717.
Crossref
Crossref
E. B. Maykov, Yu. A. Yuricheva, N. Yu. Mironov, S. F. Sokolov, S. P. Golitsyn, L. V. Rozenshtraukh & E. I. Chazov. (2015) Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter. Terapevticheskii arkhiv 87:1, pages 38.
Crossref
Crossref
Evgeny B. Maykov, Yulia A. Yuricheva, Nikolay Yu. Mironov, Sergey F. Sokolov, Sergey P. Golitsyn, Leonid V. Rosenshtraukh & Evgeny I. Chazov. (2014) Efficacy of a New Class III Drug Niferidil in Cardioversion of Persistent Atrial Fibrillation and Flutter. Journal of Cardiovascular Pharmacology 64:3, pages 247-255.
Crossref
Crossref
Constanze Schmidt, Felix Wiedmann, Patrick A. Schweizer, Hugo A. Katus & Dierk Thomas. (2014) Inhibition of cardiac two-pore-domain K+ (K2P) channels – an emerging antiarrhythmic concept. European Journal of Pharmacology 738, pages 250-255.
Crossref
Crossref
Diego Conde & Adrian Baranchuk. (2014) Vernakalant for the Conversion of Atrial Fibrillation: The New Kid On the Block?. Annals of Noninvasive Electrocardiology 19:4, pages 299-302.
Crossref
Crossref
Nicole Schmitt, Morten Grunnet & Søren-Peter Olesen. (2014) Cardiac Potassium Channel Subtypes: New Roles in Repolarization and Arrhythmia. Physiological Reviews 94:2, pages 609-653.
Crossref
Crossref
Ursula Ravens. (2014) Neue Entwicklungen in der antiarrhythmischen Therapie des VorhofflimmernsNew developments in the antiarrhythmic therapy of atrial fibrillation. Herzschrittmachertherapie + Elektrophysiologie 25:1, pages 41-46.
Crossref
Crossref
Claudia Seyler, Jin Li, Patrick A. Schweizer, Hugo A. Katus & Dierk Thomas. (2014) Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant – Comparison with flecainide. European Journal of Pharmacology 724, pages 51-57.
Crossref
Crossref
Alain Rudiger, Alexander Breitenstein, Mattia Arrigo, Sacha P. Salzberg & Dominique Bettex. (2014) Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice 2014, pages 1-7.
Crossref
Crossref
Torsten Christ. (2014) Atrial-selective Antiarrhythmic Activity by Vernakalant Fact or Fiction?. Journal of Cardiovascular Pharmacology 63:1, pages 23-24.
Crossref
Crossref
Charles Antzelevitch, Vladislav Nesterenko, John C. Shryock, Sridharan Rajamani, Yejia Song & Luiz Belardinelli. 2014. Voltage Gated Sodium Channels. Voltage Gated Sodium Channels
137
168
.
Gary Aistrup. 2014. Cardiac Arrhythmias. Cardiac Arrhythmias
305
333
.
Rosanne Varkevisser, Marcel A.G. van der Heyden, Ralph G. Tieland, Jet D.M. Beekman & Marc A. Vos. (2013) Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model. European Journal of Pharmacology 720:1-3, pages 49-54.
Crossref
Crossref
Ingemar Jacobson, Göran Duker, Malin Florentzson, Gunilla Linhardt, Emma Lindhardt, Ann-Kristin Nordkam, Annika Åstrand & Leif Carlsson. (2013) Electrophysiological Characterization and Antiarrhythmic Efficacy of the Mixed Potassium Channel-Blocking Antiarrhythmic Agent AZ13395438 In Vitro and In Vivo. Journal of Cardiovascular Pharmacology and Therapeutics 18:3, pages 290-300.
Crossref
Crossref
Erich Wettwer, Torsten Christ, Sebastian Endig, Nadiia Rozmaritsa, Klaus Matschke, Joseph J. Lynch, Marc Pourrier, John K. Gibson, David Fedida, Michael Knaut & Ursula Ravens. (2013) The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovascular Research 98:1, pages 145-154.
Crossref
Crossref
Joseph J. LynchJrJr, Christopher P. Regan, Gregory N. Beatch, Gilbert W. Gleim & Christopher J. Morabito. (2013) Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues. Journal of Cardiovascular Pharmacology 61:3, pages 226-232.
Crossref
Crossref
David Filgueiras-RamaRaphael P. MartinsSergey MironovMasatoshi YamazakiConrado J. CalvoSteve R. EnnisKrishna BandaruSami F. NoujaimJérôme KalifaOmer BerenfeldJosé Jalife. (2012) Chloroquine Terminates Stretch-Induced Atrial Fibrillation More Effectively Than Flecainide in the Sheep Heart. Circulation: Arrhythmia and Electrophysiology 5:3, pages 561-570.
Crossref
Crossref
Alexander Burashnikov, Hector Barajas-Martinez, Dan Hu, Eyal Nof, Jonathan Blazek & Charles Antzelevitch. (2012) Atrial-selective Prolongation of Refractory Period With AVE0118 is Due Principally to Inhibition of Sodium Channel Activity. Journal of Cardiovascular Pharmacology 59:6, pages 539-546.
Crossref
Crossref
Alexander BurashnikovMarc PourrierJohn K. GibsonJoseph J. LynchCharles Antzelevitch. (2012) Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel. Circulation: Arrhythmia and Electrophysiology 5:2, pages 400-408.
Crossref
Crossref
Lori D. Bash, Jessica L. Buono, Glenn M. Davies, Amber Martin, Kyle Fahrbach, Hemant Phatak, Ruzan Avetisyan & Mkaya Mwamburi. (2012) Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation. Cardiovascular Drugs and Therapy 26:2, pages 167-179.
Crossref
Crossref
Serge Sicouri, Marc Pourrier, John K. Gibson, Joseph J. Lynch & Charles Antzelevitch. (2012) Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm 9:3, pages 422-429.
Crossref
Crossref
Gerald V. Naccarelli. 2012. Electrophysiological Disorders of the Heart. Electrophysiological Disorders of the Heart
1159
1166
.
Dobromir Dobrev & Bramah N. Singh. 2012. Electrophysiological Disorders of the Heart. Electrophysiological Disorders of the Heart
1133
1157
.
Shayne Cox GadNicholas B. Norgard & Mazen S. Abu-Fadel. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Alexander Burashnikov & Charles Antzelevitch. (2011) Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacology & Therapeutics 132:3, pages 300-313.
Crossref
Crossref
Christian Torp-PedersenDimitar H. RaevGarth DickinsonNoam N. ButterfieldBrian MangalGregory N. Beatch. (2011) A Randomized, Placebo-Controlled Study of Vernakalant (Oral) for the Prevention of Atrial Fibrillation Recurrence After Cardioversion. Circulation: Arrhythmia and Electrophysiology 4:5, pages 637-643.
Crossref
Crossref
Jeff Bechard & Marc Pourrier. (2011) Atrial Selective Effects of Intravenously Administered Vernakalant in Conscious Beagle Dogs. Journal of Cardiovascular Pharmacology 58:1, pages 49-55.
Crossref
Crossref
Sean T. Duggan & Lesley J. Scott. (2011) Spotlight on Intravenous Vernakalant in Recent-Onset Atrial Fibrillation†. Drugs & Aging 28:6, pages 501-504.
Crossref
Crossref
Beth Allison, Yi Yang, Marc Pourrier & John K Gibson. (2011) Comparison of the In Vivo Hemodynamic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in a Rat Hindlimb Perfusion Model. Journal of Cardiovascular Pharmacology 57:4, pages 463-468.
Crossref
Crossref
Jeff Bechard, John Ken Gibson, Cheryl R Killingsworth, Jeffery J Wheeler, Marlowe J Schneidkraut, Jian Huang, Raymond E Ideker & Donald A McAfee. (2011) Vernakalant Selectively Prolongs Atrial Refractoriness With No Effect on Ventricular Refractoriness or Defibrillation Threshold in Pigs. Journal of Cardiovascular Pharmacology 57:3, pages 302-307.
Crossref
Crossref
U. Ravens & E. Wettwer. (2010) Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovascular Research 89:4, pages 776-785.
Crossref
Crossref
Sean T. Duggan & Lesley J. Scott. (2011) Intravenous Vernakalant. Drugs 71:2, pages 237-252.
Crossref
Crossref
David Tian & William H. Frishman. (2011) Vernakalant. Cardiology in Review 19:1, pages 41-44.
Crossref
Crossref
Stanley Nattel. (2011) From Guidelines to Bench: Implications of Unresolved Clinical Issues for Basic Investigations of Atrial Fibrillation Mechanisms. Canadian Journal of Cardiology 27:1, pages 19-26.
Crossref
Crossref
Qidong You, Qian Yang & Xiaojian Wang. 2011. Ion Channels and Their Inhibitors. Ion Channels and Their Inhibitors
117
147
.
Ursula Ravens. 2011. Heart Rate and Rhythm. Heart Rate and Rhythm
599
610
.
Ellen C. Breen & Jason X.-J. Yuan. 2011. Textbook of Pulmonary Vascular Disease. Textbook of Pulmonary Vascular Disease
539
555
.
Morten Grunnet, Bo Hjorth Bentzen, Ulrik Svane Sørensen & Jonas Goldin Diness. 2012. Reviews of Physiology, Biochemistry and Pharmacology 162. Reviews of Physiology, Biochemistry and Pharmacology 162
1
58
.
Ursula Ravens. (2010) Antiarrhythmic therapy in atrial fibrillation. Pharmacology & Therapeutics 128:1, pages 129-145.
Crossref
Crossref
Gerald V. NaccarelliAnne B. Curtis. (2010) Review: Optimizing the Management of Atrial Fibrillation: Focus on Current Guidelines and the Impact of New Agents on Future Recommendations. Journal of Cardiovascular Pharmacology and Therapeutics 15:3, pages 244-256.
Crossref
Crossref
Qian Yang, David Fedida, Hongjian Xu, Binghe Wang, Lupei Du, Xiaojian Wang, Minyong Li & Qidong You. (2010) Structure-Based Virtual Screening and Electrophysiological Evaluation of New Chemotypes of Kv1.5 Channel Blockers. ChemMedChem 5:8, pages 1353-1358.
Crossref
Crossref
Leif Carlsson, Göran Duker & Ingemar Jacobson. (2010) New pharmacological targets and treatments for atrial fibrillation. Trends in Pharmacological Sciences 31:8, pages 364-371.
Crossref
Crossref
Miki Finnin. (2010) Vernakalant: A novel agent for the termination of atrial fibrillation. American Journal of Health-System Pharmacy 67:14, pages 1157-1164.
Crossref
Crossref
Alexander Burashnikov, Andrew C Zygmunt, Jose M Di Diego, Gunilla Linhardt, Leif Carlsson & Charles Antzelevitch. (2010) AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog. Journal of Cardiovascular Pharmacology 56:1, pages 80-90.
Crossref
Crossref
Alexander Burashnikov & Charles Antzelevitch. (2010) New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology 7:3, pages 139-148.
Crossref
Crossref
Charles Antzelevitch & Alexander Burashnikov. (2010) Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. Annals of the New York Academy of Sciences 1188:1, pages 78-86.
Crossref
Crossref
Gui-Rong Li & Ming-Qing Dong. 2010. Cardiovascular Pharmacology - Heart and Circulation. Cardiovascular Pharmacology - Heart and Circulation
93
134
.
Armando Lagrutta & Joseph J. Salata. 2009. Novel Therapeutic Targets for Antiarrhythmic Drugs. Novel Therapeutic Targets for Antiarrhythmic Drugs
233
269
.
Arun Sridhar & Cynthia A. Carnes. 2009. Novel Therapeutic Targets for Antiarrhythmic Drugs. Novel Therapeutic Targets for Antiarrhythmic Drugs
479
493
.
Alexander Burashnikov & Charles Antzelevitch. 2009. Novel Therapeutic Targets for Antiarrhythmic Drugs. Novel Therapeutic Targets for Antiarrhythmic Drugs
461
478
.
Heike Wulff, Neil A. Castle & Luis A. Pardo. (2009) Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery 8:12, pages 982-1001.
Crossref
Crossref
Marisa Chard & Reza Tabrizchi. (2009) The role of pulmonary veins in atrial fibrillation: A complex yet simple story. Pharmacology & Therapeutics 124:2, pages 207-218.
Crossref
Crossref
Charles Antzelevitch & Alexander Burashnikov. (2009) Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. Journal of Electrocardiology 42:6, pages 543-548.
Crossref
Crossref
Jodene Eldstrom & David Fedida. (2009) Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels. Journal of Molecular Graphics and Modelling 28:3, pages 226-235.
Crossref
Crossref
Alexander Burashnikov & Charles Antzelevitch. (2009) New Pharmacological Strategies for the Treatment of Atrial Fibrillation. Annals of Noninvasive Electrocardiology 14:3, pages 290-300.
Crossref
Crossref
Joachim R. Ehrlich & Stanley Nattel. (2009) Novel Approaches for Pharmacological Management of Atrial Fibrillation. Drugs 69:7, pages 757-774.
Crossref
Crossref
H.-J. Schneider, O. Husser, M. Rihm, S. Fredersdorf, C. Birner, S. Dhein, F. Muders, A. Jeron, H. Goegelein, G. A. Riegger & A. Luchner. (2008) Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure. Naunyn-Schmiedeberg's Archives of Pharmacology 379:3, pages 225-232.
Crossref
Crossref
Joachim R Ehrlich & Stanley Nattel. (2009) Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Current Opinion in Cardiology 24:1, pages 50-55.
Crossref
Crossref
Jerzy Karczewski, Laszlo Kiss, Stefanie A. Kane, Kenneth S. Koblan, Robert J. Lynch & Robert H. Spencer. (2009) High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5. Biochemical Pharmacology 77:2, pages 177-185.
Crossref
Crossref
Jörn Schmitt, Joachim R. Ehrlich & Stefan H. Hohnloser. (2009) New Antiarrhythmic Drugs for the Treatment of Atrial FibrillationNeue Antiarrhythmika für die Therapie von Vorhofflimmern. Herz Kardiovaskuläre Erkrankungen 33:8, pages 562-567.
Crossref
Crossref
Peter WeekeCharlotte AnderssonBente BrendorpChristian Torp-Pedersen. (2008) Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety. Future Cardiology 4:6, pages 559-567.
Crossref
Crossref
Gerald V Naccarelli & Mario D Gonzalez. (2008) Atrial Fibrillation and the Expanding Role of Catheter Ablation: Do Antiarrhythmic Drugs Have a Future?. Journal of Cardiovascular Pharmacology 52:3, pages 203-209.
Crossref
Crossref
MARC COHEN & GERALD V. NACCARELLI. (2008) Pathophysiology and Disease Progression of Atrial Fibrillation: Importance of Achieving and Maintaining Sinus Rhythm. Journal of Cardiovascular Electrophysiology 19:8, pages 885-890.
Crossref
Crossref
John W Ford & James T Milnes. (2008) New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (IKur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value. Journal of Cardiovascular Pharmacology 52:2, pages 105-120.
Crossref
Crossref
Ursula Ravens. (2008) Potassium channels in atrial fibrillation: Targets for atrial and pathology-specific therapy?. Heart Rhythm 5:5, pages 758-759.
Crossref
Crossref
D A Saint. (2008) The cardiac persistent sodium current: an appealing therapeutic target?. British Journal of Pharmacology 153:6, pages 1133-1142.
Crossref
Crossref
Joachim R. Ehrlich, Peter Biliczki, Stefan H. Hohnloser & Stanley Nattel. (2008) Atrial-Selective Approaches for the Treatment of Atrial Fibrillation. Journal of the American College of Cardiology 51:8, pages 787-792.
Crossref
Crossref
Armando Lagrutta, Laszlo Kiss & Joseph J. Salata. 2008. Ion Channels. Ion Channels
145
168
.
Jodene Eldstrom, Zhuren Wang, Hongjian Xu, Marc Pourrier, Alan Ezrin, Ken Gibson & David Fedida. (2007) The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology 72:6, pages 1522-1534.
Crossref
Crossref